Sodium/glucose cotransporter 2 (SGLT2) is the predominant mediator of renal glucose
reabsorption and is an emerging molecular target for the treatment of diabetes. We identified a …

Dysregulation of the complement system is linked to the pathogenesis of a variety of
hematological disorders. Eculizumab, an anti-complement C5 monoclonal antibody, is the current …

The liver plays a major role in whole-body energy homeostasis by releasing secretory factors,
termed hepatokines. To identify novel target genes associated with insulin resistance, we …

Although excessive fructose intake is epidemiologically linked with dyslipidemia, obesity,
and diabetes, the mechanisms regulating plasma fructose are not well known. Cells …

To understand the risk of hypoglycemia associated with urinary glucose excretion (UGE)
induced by sodium-glucose cotransporter (SGLT) inhibitors, it is necessary to know the …

By using a DNA fragment of Escherichia coli ffh as a probe, the Bacillus subtilis ffh gene was
cloned. The complete nucleotide sequence of the cloned DNA revealed that it contained …

The metabolism and drug–drug interaction (DDI) risk of tofogliflozin, a potent and highly
specific sodium-glucose co-transporter 2 inhibitor, were evaluated by in vitro studies using …

We cloned a Bacillus subtilis gene (srb) encoding a homologue of the mammalian signal
recognition particle receptor α-subunit (SRα). The gene is 987 bp in length and encodes a 329-…

B. subtilis Ffh is a homologue of SRP54, which is one component of the mammalian signal
recognition particle. B. subtilis Ffh was expressed in E. coli as a derivative with a hexa …

Sodium-glucose cotransporter 2 (SGLT2) inhibitors showed a glucose lowering effect in
type 2 diabetes patients through inducing renal glucose excretion. Detailed analysis of the …